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Abstract RB mRNA increases during terminal differentiation 
of C2 myoblasts. We demonstrate that RB promoter activity 
increases about 4-fold during differentiation. The increase of RB 
promoter activity was reduced when a point mutation was 
designed in the ATF site. In a gel shift assay of the ATE site, two 
specific bands were observed. One of them, with the lower 
mobility, disappeared during differentiation. This band reacted 
with an antibody against ATF-1. We cotransfected an RB 
promoter-luciferase plasmid with the TREB36/ATF-1 plasmid. 
ATF-1 suppressed the activity of the wild-type RB promoter but 
not of that with a point mutation at the ATF site. These results 
suggest that the ATF site of the RB promoter is a responsive 
element during myogenic differentiation of C2 cells. We 
hypothesize that RB promoter activity is stimulated partially 
due to the dissociation of ATF-1, which suppresses the promoter 
activity through the ATF site in C2 myoblasts. 
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1. Introduction 
The retinoblastoma susceptibility gene (RB) is the first iden- 
tified prototype of a tumor suppressor gene [l]. Inactivation 
of the RB is associated with the etiology of a number of hu- 
man tumors [2]. Expression of the RB protein in RB-negative 
cells suppresses the neoplastic phenotype and arrests the cells 
in late Gl phase [3,4]. Thus, the RB protein appears to play 
an important role in suppressing cell growth. 
The RB protein is a nuclear phosphoprotein that undergoes 
cell cycle dependent changes in its phosphorylation status. 
The activity of the RB protein has been supposed to be con- 
trolled by its phosphorylation [2]. However, during terminal 
differentiation of the mouse skeletal muscle cell line C2, both 
the mRNA and protein of the RB have been markedly in- 
duced [5]. Also in other cell lines, such as mouse skeletal 
myoblast S2 cells, mouse erythroleukemic MEL cells and 
mouse embryonal carcinoma P19 cells, the RB mRNA in- 
creases during differentiation [68]. However, these studies 
did not describe whether the increase occurred at transcrip- 
tional or post-transcriptional level. 
Skeletal muscle cells are an excellent system for investigat- 
ing the molecular mechanism of differentiation, because they 
exhibit permanent withdrawal from the cell cycle and the re- 
markable phenotype to form multinucleated myotubes [9]. 
The terminal differentiation of muscle cells requires RB pro- 
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tein, because multinucleated myotubes from mice deficient in 
the RB gene cannot maintain the differentiated state and are 
induced by serum to reenter the cell cycle [lo]. In myogenic 
differentiation, the RB protein must interact directly through 
a pocket domain with MyoD protein [ll]. Moreover, the RB 
gene is transactivated by MyoD at the transcriptional level 
[12]. From these perspectives, the RB protein is an important 
regulator of muscle differentiation. 
In the present study, we found that RB promoter activity 
increased about 4-fold during the differentiation of mouse 
skeletal muscle C2 cells. We identified a responsive element 
during muscle differentiation as an ATF site, where we found 
oncogenic germ-line mutation in one hereditary retinoblasto- 
ma family [13]. In a gel shift assay of the ATF site, a band 
that disappeared during myogenesis reacted with an antibody 
against ATF-I TREB36/ATF-1 protein [14] suppressed the 
RB promoter activity specifically through the ATF site in 
cotransfection experiments. The increase of RB promoter ac- 
tivity during muscle differentiation of C2 cells is likely to be 
ascribed to the dissociation of ATF-1 protein suppressing the 
RB promoter. 
2. Materials and methods 
2.1. Cell lines and culture conditions 
The mouse skeletal muscle cell line C2 [15] was maintained at 37OC 
in 5% CO2 in Dulbecco’s modified Eagle’s (DME) medium containing 
10% fetal calf serum (growth medium). To induce terminal differentia- 
tion, 2 X lo5 cells were plated in the growth medium on 3.5 cm diam- 
eter dishes and maintained for 24 h, then the medium was changed 
to DME medium containing 5% horse serum (differentiation me- 
dium). 
2.2. Plasmid preparation and mutagenesis of the RB promoter 
The wild-type human RB promoter-luciferase fusion plasmid, 
pXRP1, and the various mutant RB promoter-luciferase fusion plas- 
mids were generated as described [ 13,161. We confirmed by sequencing 
that the RB promoter constructs had no cloning-induced point muta- 
tions. 
2.3. Stable transfection 
Wild and mutant human RB promoter-luciferase fusion plasmids, 
and a plasmid conferring neomycin resistance, pSV2neo, were co- 
transfected into C2 mycoblasts by the Chen-Okayama method as 
described [17]. About 3 weeks later, the G418-resistant cells were 
isolated as a mixture of multiple colonies, and were expanded in a 
manner that was independent of the copy number and the integration 
locus in order to avoid clonal heterogeneity [18]. 
2.4. Luciferase assay 
Cells were maintained in 3.5 cm diameter culture dishes, washed 
twice with Ca2+- and Mg*+-free phosphate-buffered saline (PBS), then 
cell lysates were collected and stored at -70°C. Luciferase activity 
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was measured under the conditions at the time as described [19], and 
was standardized by the amount of cellular protein in all samples or 
chloramphenicol acetyltransferase (CAT) activity driven by pSV2CAT 
as an internal control for transfection efficiency in some transient 
transfection experiments (data not shown). The luciferase assays 
were performed in triplicate and all experiments were repeated at least 
three times. 
2.5. Gel shift assay 
We prepared a nuclear extract and a whole cell extract from C2 
myoblasts and C2 myotubes as described [20,16]. Radiolabeled dou- 
ble-stranded DNA was generated by annealing complementary oligo- 
mers with 5’ overhangs then filling in the recessed 3’ ends with dNTPs 
including 32P-labeled dCTP, using the Klenow fragment of DNA 
polymerase I. All assayed sequences have flanked partial Hind111 
and S&I recognition sequences not present in the RB gene. The 
DNA fragments had the following sequences (complete sense strand) 
(Fig. 2A): ATF-WT (wild-type ATF site from the RB pro- 
moter), AGCTCGGAAGTGACGTTTTCCCTCGA; ATF-MT (mu- 
tant ATF site from the RB promoter), AGCTCGGAAGT- 
GACTTTTTCCCTCGA; RBF-1 (RBF-l/E4TFl site from the RB 
promoter) [13,21], AGCTGCCGCGGGCGGAAGTTCGA; RBF- 
l+ATF (from the RBF-lIE4TFl site to the ATF site from the RB 
promoter), AGCTGCCGCGGGCGGAAGTGACGTTTTCCCTC- 
GA. Protein and DNA binding reactions were carried out as follows. 
1 ng of radiolabeled oligomer DNA, 7 ug of nuclear extracts, and 
1 ug of poly(dIdC) were incubated in a buffer containing 20 mM 
HEPES (pH 7.4), 40 mM KCl, 1 mM MgClz, 0.1 mM EDTA, and 
0.1% Nonidet P-40 for 30 min at room temperature. When the anti- 
ATF-1, anti-ATF-2, or anti-CREB-1 antibody (Santa Cruz Biotech- 
nology) was used, 1 ug of the antibody was added and incubated for 
an additional 30 min at room temperature. Subsequently, reaction 
mixtures were loaded onto 4% polyacrylamide gels (acrylamide:bis- 
acrylamide = 20: 1) and run in 0.25 x Tris-borate-EDTA buffer at 
room temperature at 200 V for 1.5 h. 
to a polyvinyldifluoride membrane (Millipore). Membranes were 
washed with rinse buffer (PBS containing 0.1% T&on-X and 0.1% 
Tween-20) at room temperature for 15 min and incubated in blocking 
buffer (5% nonfat milk in rinse buffer). The membrane was then in- 
cubated with purified anti-ATF-1 antibody (0.5 @ml) in rinse buffer 
for 1 h at room temperature and washed three times with rinse buffer. 
Next, the membrane was incubated with 1:4000 diluted anti-mouse 
IgG, horseradish peroxidase-linked whole antibody (Amersham) in 
rinse buffer for 1 h at room temperature. After three washes, mem- 
branes were developed with enhanced chemiluminescence (ECL) Wes- 
tern blotting detection reagents (Amersham). 
2.7. Transient transfection 
DNA was transfected into cells by the calcium phosphate copre- 
cipitation method as described [22]. Each transfection mixture con- 
tained 2 ug of the RB promoter-luciferase fusion plasmid as a reporter 
and 4 ug of the TREB36/ATF-1 expression plasmid [23] as an effec- 
tor. After a 48 h incubation, the cells were harvested, and the cell 
lysates were used for the luciferase assay as described above. The same 
results were obtained when luciferase activity was standardized by the 
amount of cellular protein or CAT activity driven by pSV2CAT as an 
internal control. 
3. Results 
2.6. Western blotting analysis 
Nuclear cell extracts were analyzed with 10% sodium dodecyl sul- 
fate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
To investigate whether or not the expression of the RB gene 
is regulated at the transcriptional level, we established mouse 
skeletal myoblast C2 cells, in which human RB promoter-lu- 
ciferase fusion plasmids were stably transfected. We traced 
changes in the RB promoter activity during myogenesis of 
these cells by means of a luciferase assay. As shown in Fig. 
lA, the RB promoter activity increased about 2.9-fold 24 h 
after changing to the differentiation medium, and about 4% 
fold in the terminally differentiated myotubes 96 h after the 
shift. The increase in the activity correlates with the accumu- 
lation of RB mRNA during myogenic differentiation, which 
[RLU/ yg protein] 
800 
600 
[RLU/ pg protein] 
Fig. 1. Promoter activities of RB and cyclin A during muscle cell differentiation. A: The RB promoter activity increases during muscle cell dif- 
ferentiation. B: The cyclin A promoter activity decreases during muscle cell differentiation. Relative luciferase activity is shown as raw light 
units (RLU) per ug protein in cell lysates. The luciferase assays were performed in triplicate and the data are shown as means f S.E. Signifi- 
cance was calculated against the value from myoblasts. *PC 0.05. MB: myoblasts, MT: myotubes. 
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has been reported [5]. On the other hand, in the C2 myoblasts 
into which a cyclin A promoter-luciferase fusion plasmid [14] 
was stably transfected, the cyclin A promoter activity de- 
creased markedly, as the cells differentiated into myotubes 
(Fig. 1B). The decrease in cyclin A promoter activity was 
consistent with reports that cyclin A mRNA decreased during 
myogenic differentiation [24]. In addition, when we used hu- 
man osteosarcoma MG63 cells into which human RB promo- 
ter-luciferase fusion plasmids were stably transfected, the RB 
promoter activity did not increase by serum depletion (data 
not shown). These results indicate that during muscle cell 
differentiation, human RB promoter activity specifically in- 
creases. 
To elucidate which promoter element is involved in the up- 
regulation of the RB promoter in muscle cell differentiation, 
we generated a series of plasmid constructs of deleted or point 
mutated RB promoters as shown in Fig. 2A [13,16]. We then 
stably transfected a series of mutant RB promoters-luciferase 
fusion plasmids and identified the differentiation responsive 
element of the RB promoter. Luciferase activity was assayed 
using the lysates prepared from C2 myoblasts and from C2 
myotubes. We compared the relative luciferase activity of C2 
myotubes with that of C2 myoblasts in each established cell 
line (Fig. 2B). The promoter activity with each mutation in 
the stably transfected cell lines does not necessarily reflect the 
exact effect of each mutation, perhaps because stably trans- 
fected copies of each plasmid might differ in each established 
cell line. Therefore, as shown in Fig. 2B, we determined the 
fold induction of the RB promoter activities during differen- 
tiation, showing ratios of luciferase activities in myotubes 
versus myoblasts for different RB promoter constructs. Dur- 
ing muscle cell differentiation, wild-type RB promoter activity 
from the pXRP1 plasmid increased about 3.7-fold. In con- 
trast, the activity of pXRP2, including the point mutation at 
the ATF site, increased only 1.4-fold. The activities of the 
other deleted or mutated plasmids increased 2.44.5-fold. 
These results suggest that the ATF site is a muscle differentia- 
tion-responsive element. 
To investigate changes in the nuclear factors that bind to 
the ATF and RBF-lIE4TFl sites of the RB promoter during 
muscle cell differentiation, we prepared nuclear extracts from 
C2 myoblasts and C2 myotubes. Incubation of the nuclear 
extracts with 32P-labelled oligonucleotides resulted in the for- 
mation of a specific protein-DNA complex as shown in Fig. 
3A. When we used the wild-type RBF-1 +ATF sequences from 
the RB promoter (RBF-l+ATF) as a probe, seven specific 
bands were detected in the extracts from C2 myoblasts (Fig. 
3A, lane 1). The intensity of band A decreased in the presence 
of competing wild-type ATF sequence from the RB promoter, 
designated ATF-WT (Fig. 3A, lane 2). Band A was therefore 
thought to be a member of the ATF family. In contrast, the 
intensity of other bands was reduced in the presence of a 
competing wild-type RBF-1 sequence (Fig. 3A, lane 3). 
They consequently seemed to be proteins binding to the 
RBF-lIE4TFl site. However, in C2 myotubes, band A was 
barely detectable (Fig. 3A, lane 7). The disappearance of band 
A suggested its implication in enhancing RB promoter activ- 
ity. To identify the band A protein regarded as a member of 
the ATF family, we added two anti-ATF antibodies to the 
nuclear extracts from C2 myoblasts and C2 myotubes, and 
performed a supershift assay using the RBF-l+ATF se- 
quences as a probe. Interestingly, co-incubation with the anti- 
body to ATF-1 supershifted band A (Fig. 3A, lane 5), whereas 
that to ATF-2 did not (Fig. 3A, lane 6). When we used ATF- 
WT as a probe in the gel shift assay, there were at least two 
specific bands from the nuclear extracts of C2 myoblasts (la- 
belled A and B, shown in Fig. 3B, lane 1). The intensity of 
these two bands was reduced in the presence of competing 
ATF-WT (Fig. 3B, lane 2), but not in the presence of the 
competing mutant ATF sequence, ATF-MT (Fig. 3B, lane 
3). During muscle cell differentiation, band A declined and 
was barely evident in C2 myotubes (Fig. 3B, lane 7). When 
anti-ATF antibodies were added to the nuclear extracts from 
C2 myoblasts and C2 myotubes, the antibody against ATF-1 
supershifted band A (Fig. 3B, lane 4), whereas the antibodies 
against ATF-2 and CREB-1 did not (Fig. 3B, lanes 5, 6). 
Additionally, we confirmed in the gel shift assay of the ATF 
site that the disappearance of the band A correlated with the 
A pxAp3 pxRPz pEz3 
-207 i ; G-i-176 
GCCGCGGGCOOAAGTGACGTTTTCCCGCGGTT 
- ATF 
0 
ATG 
pXRP1 
pXRP2 
-4 
1 PxAPl 
-4 
1 pAuP 
-4 
1 pxAp3 
-4 
pXRP3 
pXRPlID6 
pXRP5 
I 1 I-lpXRPlID6 pXRP7 3.4 
-206 -184 -4 I 
I 1 pxAp5 1 2 3 4 5 
-686 -182 Fold Induction of Luciferase Activity 
I I pxAp7 (C2 myotubes / C2 myoblasts) 
Fig. 2. Mapping of the responsive element during muscle cell differentiation. A: The sequence of the essential RB promoter region and the 
schematic diagram of the wild-type and several mutants. The sequence is numbered using the first base of the initiating methionine codon as 0. 
B: The enhancement of the RB promoter activity in the wild-type and the mutant RB promoters during muscle cell differentiation. Shown is 
the relative luciferase activity (the activity in myotubeskhat in myoblasts) indicated as fold induction. Data are shown as means of four inde- 
pendent experiments. 
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Whole cell Nuclear 
extract extract 
Fig. 4. Down-regulation of TREB36/ATF-1 protein during muscle 
cell differentiation. Whole cell extracts and nuclear extracts were 
prepared from C2 myoblasts and C2 myotubes. After 20 ug of 
whole cell extracts or nuclear extracts per lane were analyzed by 
SDS-PAGE, they were transferred to nitrocellulose membrane and 
the Western blotting analysis was performed using the antibody to 
ATF-1 as described in Section 2. These findings were confirmed by 
two independent samples of C2 myoblasts and C2 myotubes. 
gradual induction of RB promoter activity during terminal 
differentiation (data not shown).’ On the other hand, when 
we used the RBF-l/E4TF-1 sequence as a probe, there was 
little difference in the band profiles in the gel shift assay per- 
formed during muscle cell differentiation (data not shown). 
These data suggest that the protein dissociated from the 
ATF site of the RB promoter during differentiation is related 
to ATF-1. 
To examine the expression of ATF-1 protein during myo- 
genesis, we performed Western blotting analysis using nuclear 
extracts or whole cell extracts of C2 cells. As shown in Fig. 4, 
ATF-1 protein markedly decreased during muscle cell differ- 
entiation in both whole cell and nuclear extracts of C2 cells. 
The reduction of ATF-1 protein during differentiation was 
more evident in nuclear extracts than in whole cell extracts, 
suggesting that the nuclear distribution of ATF-1 protein was 
reduced during myogenic differentiation. Therefore, we con- 
clude that the dissociation of ATF-1 protein from the ATF 
site of the RB promoter during myogenesis is caused by the 
down-regulation of ATF-1 protein during myogenesis. 
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We then postulated that ATF-1 binds to the ATF site and 
suppresses RB promoter activity through the site in C2 myo- 
blasts. To clarify the role of ATF-1 in the transcription of the 
RB gene in muscle cells, we cotransfected the wild-type RB 
promoter-luciferase fusion plasmid, pXRP1, with the 
TREB36/ATF-1 expression plasmid, pCG-T36, in C2 myo- 
blasts. As shown in Fig. 5, the expression of TREB36/ATF- 
1 down-regulated the RB promoter activity to about 37% of 
the control, whereas TREB36/ATF-1 expression did not sup- 
press the RB promoter activity when the ATF site was mu- 
tated (pXRP2). Therefore, the TREB36/ATF-1 protein specif- 
ically suppresses the RB promoter through its ATF site in C2 
myoblasts. 
4. Discussion 
The expression of the RB gene has been shown to increase 
at the mRNA level during differentiation in mouse skeletal 
muscle C2 cells [5]. In the present study, we found that RB 
promoter activity increases from the early stage of differentia- 
tion and reaches about 4-fold in terminally differentiated C2 
cells. We then identified the ATF site as a responsive element 
of the RB promoter during myogenic differentiation of C2 
cells. We and others have described three major transcrip- 
tional factor-binding sites, RBF-l/E4TFl site overlapping 
the Sp-1 site [13,21], ATF site [13], and E2F site [16,25] in 
the RB promoter. Human and mouse RB promoters display 
high homology in the three major sites described above [26]. 
Furthermore, germ-line mutations in the RBF-lIE4TFl and 
ATF sites in the human RB promoter result in hereditary 
retinoblastoma because of a quantitative decrease in the ac- 
tivity of the RB promoter using African monkey kidney CV-1 
cells [13]. Also in this study, the mutation at the ATF site 
actually reduced the RB promoter activity in C2 mouse myo- 
blast cells. These findings indicate that the ATF site of the RB 
promoter is an essential transactivating site suggesting the 
existence of a transactivator on the site. However, in this 
study, during skeletal muscle cell differentiation, the RB pro- 
moter activity increased through the ATF site, whereas ATF- 
1 was depleted in the gel shift assay. In addition, TREB361 
ATF-1 suppressed the RB promoter activity through the ATF 
site. Thus, we hypothesize that the ATF-1 specifically binding 
to the ATF site of the RB promoter in C2 myoblasts has 
a suppressive effect on the RB promoter. During muscle dif- 
ferentiation, the ATF-1 protein decreases and thus RB pro- 
moter activity might increase, being free from the suppres- 
sion by ATF-1. It should be noted that ATF-1 works as 
a suppressor on the ATF site of the RB promoter in C2 
t 
Fig. 3. A: Gel shift assay of sequences including the RBF-l+ATF site from the promoter of the RB gene. Lanes l-6, nuclear extracts from C2 
myoblasts; lanes 7-12, nuclear extracts from C2 myotubes; lanes 1 and 7, radiolabeled, wild-type of the RBF-l+ATF sequences with nuclear 
extracts; lanes 2 and 8, the same as lanes 1 and 7, but with 20-fold molar excess of the competitors of the ATF sequence; lanes 3 and 9, the 
same as lanes 1 and 7, but with 20-fold molar excess of the competitors of the RBF-1 sequence; lanes 4 and 10, the same as lanes 1 and 7, 
but with 20-fold molar excess of the competitors of the RBF-l+ATF sequences; lanes 5 and 11, the same as lanes 1 and 7, but with 1 pg of 
anti-ATF-1 antibody; lanes 6 and 12, the same as lanes 1 and 7, but with 1 pg of anti-ATF-2 antibody. The arrow labeled A indicates a com- 
plex binding to the ATF site. Other complexes bound to the RBF-1 site. The arrow labeled S indicates a supershifted band. B: Gel shift assay 
of sequences including the ATF site from the RB promoter. Lanes l-6, nuclear extracts from C2 myoblasts; lanes 7-12, nuclear extracts from 
C2 myotubes; lanes 1 and 7, radiolabeled, wild-type of the ATF sequence with nuclear extracts; lanes 2 and 8, the same as lanes 1 and 7, but 
with 20-fold molar excess of the competitors of the ATF sequence; lanes 3 and 9, the same as lanes 1 and 7, but with 20-fold molar excess of 
the mutant ATF sequence; lanes 46 and lo-12 demonstrate the effect of anti-ATF-1 (TREB36), ATF-2 or CREB-1 antibody on the ATF 
complexes. Lanes 4 and 10, the same as lanes 1 and 7, but with 1 pg of anti-ATF-1 antibody; lanes 5 and 11, the same as lanes 1 and 7, but 
with 1 pg of anti-ATF-2 antibody; lanes 6 and 12, the same as lanes 1 and 7, but with 1 pg of anti-CREB-1 antibody. The arrows labeled A 
and B indicate complexes binding to the ATF site. The arrow labelled S’ indicates a supershifted band. 
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5 [RLU/ pg protein] 
PXWl 2yg 2pg t-1 C-1 
PXW2 c-1 t-1 2wz 2!% 
PCG-BL 4pg (-) 4pg (9 
pCG-T36 (-) 4clg (-) 4p.g 
Fig. 5. The TREB36/ATF-1 protein suppresses the RB promoter ac- 
tivity in the C2 myoblasts. The TREB36/ATF-1 expression plasmid, 
pCG-T36, or its empty vector, pCG-BL, was cotransfected with the 
wild-type (pXRP1) or mutant ATF (pXRP2) of the RB promoter- 
luciferase fusion plasmid in the C2 myoblasts. Relative luciferase ac- 
tivity is shown by raw light units (RLU) per kg protein in cell ly- 
sates. The luciferase assay was performed in triplicate and the data 
are shown as means f SE. ‘P < 0.05. 
myoblasts, whereas the ATF site is a positive transcriptional 
site [13]. 
Consistent with this finding, in CCL64 mink lung epithelial 
cells, ATF-I slightly down-regulates the RB promoter activity 
[27]. On the other hand, although ATF-2 had been reported 
to activate the RB promoter [27], it could not enhance RB 
promoter activity in C2 cells (data not shown) and did not 
bind to the ATF site of the RB promoter (Fig. 3B). In addi- 
tion, CREB-1 protein did not bind to the ATF site as shown 
in Fig. 3B. These results suggest that the activators on the 
ATF site might be some other ATF family proteins including 
novel ones. One possibility is that the band B protein shown 
in Fig. 3B may be an ATF protein activating the ATF site of 
the RB promoter. On the other hand, Shiio et al. suggest that 
Bcl-3 enhances the RB gene promoter through the E4TFl site 
during muscle differentiation [28]. However, expression of Bcl- 
3 mRNA is highest at 48 h, and then it gradually decreases. 
Therefore, the induction of Bcl-3 might be involved in early 
induction of RB mRNA, and we propose that the dissociation 
of ATF-1 partially contributes to the expression of the RB 
gene during terminal differentiation of C2 cells. As the next 
step, we plan to examine if the increase of the RB promoter 
activity during differentiation in other cell lines is caused by 
the same mechanism. 
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